COMMUNIQUÉS West-GlobeNewswire

Targeting The Mutant: NTHI’s NEO100 Data Could Open a New Front in the Fight Against Brain Cancer
12/08/2026
DALLAS, Aug. 12, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings (NASDAQ: NTHI) has delivered the kind of clinical update that can change the conversation around a small biotechnology company: its Phase 2a study of [...]
Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
12/08/2026
WILMETTE, Ill., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with [...]
Conavi Medical Corp. Announces Closing of $10M Public Offering
12/08/2026
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (“ Conavi ” or the “ Company ”), a commercial stage [...]
Kyowa Kirin Introduces Family Outreach Initiative to Support Families Living with XLH
12/08/2026
New resources and events help guide meaningful conversations about the hereditary nature of XLH PRINCETON, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd., [...]
Ventripoint Expands Subscription Access for FDA-Cleared AI Cardiac Imaging
12/08/2026
Commercial initiative aims to make VMS+ easier for hospitals to evaluate and adopt TORONTO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV: VPT; OTC: VPTDF), a [...]
LiveWorld Reports Second Quarter 2026 Financial Results
12/08/2026
LiveWorld continues to Increase its AI investment CAMPBELL, Calif. and NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- LiveWorld, Inc. (OTC Markets: LVWD), today announced financial results for second quarter 2026. Three [...]
Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents
12/08/2026
-- New U.S. and international patents complement existing delivery system patents, extending global IP coverage for the FemBloc solution -- ATLANTA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a [...]
FDA Grants Breakthrough Device Designation to Freenome’s Blood-Based SimpleScreen™ Lung Cancer Screening Test
12/08/2026
Investigational AI-powered multiomic test is being developed for adults ages 50-80 at high risk who are not currently participating in guideline-recommended lung cancer screening BRISBANE, Calif., Aug. 12, 2026 (GLOBE [...]
Olympia Pharmaceuticals Advances Longevity Offerings With Advanced Injectable CoQ10 Formulation
12/08/2026
Formulated in an advanced MCT oil base, the new 20 mg/mL formulation offers healthcare providers an effective, patient-friendly option for mitochondrial and cardiovascular health ORLANDO, Fla., Aug. 12, 2026 (GLOBE [...]
AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ Article
12/08/2026
Article by CEO Thomas K. Equels calls for proactive evaluation of broad-spectrum antiviral countermeasures before novel viral threats emerge Highlights Company’s investigational drug Ampligen® (rintatolimod) and its [...]
ENvue Medical Secures Equity Financing Facility of Up to $50 Million to Support Commercial Growth, Technology Expansion and Strategic Acquisitions
12/08/2026
TYLER, Texas, Aug. 12, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) ("ENvue" or the "Company"), a commercial-stage medical technology company, today announced that it has entered into a securities [...]
Biomimetic Innovations Ltd announces First-in-Human application of OsStic™ Injectable Synthetic Bone Void Filler
12/08/2026
SHANNON, Ireland, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Biomimetic Innovations Ltd, an affiliate of PBC Biomed - an Irish medical device company specialising in biomimetic materials, today announced the successful First-in- [...]
Mapi Pharma Announces Initial Phase I/IIa Clinical Results Supporting Continued Development of Once-Monthly Cariprazine Depot
12/08/2026
NESS ZIONA, Israel, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd. (“Mapi” or the “Company”), a late-stage clinical biopharmaceutical company specializing in long-acting injectable therapies, today announced initial [...]
Tris Pharma Expands Support for People Living with ADHD Through New Partnerships with Calm Health and ADHD Central
12/08/2026
Initiatives Provide New DYANAVEL® XR Patients With Digital Wellness Resources and Practical Organization Tools Designed to Support ADHD Care Beyond Medication MONMOUTH JUNCTION, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- [...]
Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business Areas
12/08/2026
Dyadic to host earnings call on August 12 at 5:00 pm ET JUPITER, Fla., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied [...]
Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers
12/08/2026
Contrasting Science with Revolution Medicines and Erasca MELBOURNE, Australia, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused [...]
Aprea Therapeutics Announces Second Quarter 2026 Financial Results
12/08/2026
Enrollment in the ongoing Phase 1 dose escalation ACESOT-1051 trial of oral WEE1 inhibitor APR-1051 is accelerating as dose escalation advances Aprea plans to advance APR-1051 in uterine serous carcinoma (USC), and [...]
Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
12/08/2026
Rapid, Positive Clinical Outcomes in GBS FORWARD Study Reinforce Consistency and Reproducibility of Tanruprubart Treatment Effect Demonstrated in Phase 3 and Real-World Evidence Studies; BLA Submission Expected in Q4 [...]
Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study
12/08/2026
BRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases [...]

Pages